MicroRNA 210 as a Biomarker for Congestive Heart Failure-Reference-Cited by-同舟云学术

MicroRNA 210 as a Biomarker for Congestive Heart Failure

Published:2013 Issue:1 Volume:36 Page:48-54
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Endo Kosuke¹,Naito Yukiko¹,Ji Xu¹,Nakanishi Michio²,Noguchi Teruo²,Goto Yoichi²,Nonogi Hiroshi²,Ma Xiao¹,Weng Huachun¹,Hirokawa Go¹,Asada Takashi²,Kakinoki Sachiro³,Yamaoka Tetsuji³,Fukushima Yasue¹,Iwai Naoharu¹

Affiliation:

1. Department of Genomic Medicine, National Cerebral and Cardiovascular Center

2. Department of Cardiovascular Medicine, Clinical Laboratory, National Cerebral and Cardiovascular Center

3. Department of Biomedical Engineering, National Cerebral and Cardiovascular Center

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/36/1/36_b12-00578/_pdf

Cited by 92 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mitochondrial dysfunction due to miR-210/Drd5/ROS axis is a potential mechanism of heart failure;International Journal of Cardiology;2024-05

2. Exercise-Induced miR-210 Promotes Cardiomyocyte Proliferation and Survival and Mediates Exercise-Induced Cardiac Protection against Ischemia/Reperfusion Injury;Research;2024-01

3. Predictive biomarkers for the early detection and management of heart failure;Heart Failure Reviews;2023-09-13

4. miRNAs orchestration of cardiovascular diseases – Particular emphasis on diagnosis, and progression;Pathology - Research and Practice;2023-08

5. The promise of RNA-based therapeutics in revolutionizing heart failure management – a narrative review of current evidence;Annals of Medicine & Surgery;2023-07-31